91制片厂

Published on Market Research Reports庐 Inc. ()

Home > Global Ischemic Optic Neuropathy Treatment Market Growth (Status and Outlook) 2025-2031

Global Ischemic Optic Neuropathy Treatment Market Growth (Status and Outlook) 2025-2031

Publication ID: 
LPI06251292
Publication Date: 
June 27, 2025
Pages: 
94
Publisher: 
LPI
Countries: 
Global [1]
USD 3,660.00

Please choose the suitable license type from above. More details are given under tab "Report License Types" below.

Pharmaceutical Manufacturing [2]
Healthcare [3]
Pharma & Healthcare [4]
Description: 

The global Ischemic Optic Neuropathy Treatment market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
Ischemic optic neuropathy refers to a condition in which there is inadequate blood supply (ischemia) to the optic nerve, leading to damage and potential vision loss. There are two main types of ischemic optic neuropathy: anterior ischemic optic neuropathy (AION) and posterior ischemic optic neuropathy (PION). The treatment approach for ischemic optic neuropathy depends on the specific type and underlying causes. It"s important to note that while some interventions may be attempted, the prognosis for vision recovery can vary.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淚schemic Optic Neuropathy Treatment Industry Forecast鈥� looks at past sales and reviews total world Ischemic Optic Neuropathy Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Ischemic Optic Neuropathy Treatment sales for 2025 through 2031. With Ischemic Optic Neuropathy Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ischemic Optic Neuropathy Treatment industry.
This Insight Report provides a comprehensive analysis of the global Ischemic Optic Neuropathy Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Ischemic Optic Neuropathy Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Ischemic Optic Neuropathy Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ischemic Optic Neuropathy Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ischemic Optic Neuropathy Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Ischemic Optic Neuropathy Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
Oral
Injection
Segmentation by Application:
Hospital
Designated Pharmacy
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AbbVie
Eli Lily Company
GlaxoSmithKline
Pfizer Inc.
Teva Pharmaceuticals
Bausch Health Companies
F. Hoffmann-La Roche AG
Bayer AG
Sanofi A.S.
Bristol-Myers Squibb and Company

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents: 

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Ischemic Optic Neuropathy Treatment Market Size (2020-2031)
2.1.2 Ischemic Optic Neuropathy Treatment Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Ischemic Optic Neuropathy Treatment by Country/Region (2020, 2024 & 2031)
2.2 Ischemic Optic Neuropathy Treatment Segment by Type
2.2.1 Oral
2.2.2 Injection
2.3 Ischemic Optic Neuropathy Treatment Market Size by Type
2.3.1 Ischemic Optic Neuropathy Treatment Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Ischemic Optic Neuropathy Treatment Market Size Market Share by Type (2020-2025)
2.4 Ischemic Optic Neuropathy Treatment Segment by Application
2.4.1 Hospital
2.4.2 Designated Pharmacy
2.4.3 Others
2.5 Ischemic Optic Neuropathy Treatment Market Size by Application
2.5.1 Ischemic Optic Neuropathy Treatment Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Ischemic Optic Neuropathy Treatment Market Size Market Share by Application (2020-2025)
3 Ischemic Optic Neuropathy Treatment Market Size by Player
3.1 Ischemic Optic Neuropathy Treatment Market Size Market Share by Player
3.1.1 Global Ischemic Optic Neuropathy Treatment Revenue by Player (2020-2025)
3.1.2 Global Ischemic Optic Neuropathy Treatment Revenue Market Share by Player (2020-2025)
3.2 Global Ischemic Optic Neuropathy Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Ischemic Optic Neuropathy Treatment by Region
4.1 Ischemic Optic Neuropathy Treatment Market Size by Region (2020-2025)
4.2 Global Ischemic Optic Neuropathy Treatment Annual Revenue by Country/Region (2020-2025)
4.3 Americas Ischemic Optic Neuropathy Treatment Market Size Growth (2020-2025)
4.4 APAC Ischemic Optic Neuropathy Treatment Market Size Growth (2020-2025)
4.5 Europe Ischemic Optic Neuropathy Treatment Market Size Growth (2020-2025)
4.6 Middle East & Africa Ischemic Optic Neuropathy Treatment Market Size Growth (2020-2025)
5 Americas
5.1 Americas Ischemic Optic Neuropathy Treatment Market Size by Country (2020-2025)
5.2 Americas Ischemic Optic Neuropathy Treatment Market Size by Type (2020-2025)
5.3 Americas Ischemic Optic Neuropathy Treatment Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ischemic Optic Neuropathy Treatment Market Size by Region (2020-2025)
6.2 APAC Ischemic Optic Neuropathy Treatment Market Size by Type (2020-2025)
6.3 APAC Ischemic Optic Neuropathy Treatment Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Ischemic Optic Neuropathy Treatment Market Size by Country (2020-2025)
7.2 Europe Ischemic Optic Neuropathy Treatment Market Size by Type (2020-2025)
7.3 Europe Ischemic Optic Neuropathy Treatment Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ischemic Optic Neuropathy Treatment by Region (2020-2025)
8.2 Middle East & Africa Ischemic Optic Neuropathy Treatment Market Size by Type (2020-2025)
8.3 Middle East & Africa Ischemic Optic Neuropathy Treatment Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Ischemic Optic Neuropathy Treatment Market Forecast
10.1 Global Ischemic Optic Neuropathy Treatment Forecast by Region (2026-2031)
10.1.1 Global Ischemic Optic Neuropathy Treatment Forecast by Region (2026-2031)
10.1.2 Americas Ischemic Optic Neuropathy Treatment Forecast
10.1.3 APAC Ischemic Optic Neuropathy Treatment Forecast
10.1.4 Europe Ischemic Optic Neuropathy Treatment Forecast
10.1.5 Middle East & Africa Ischemic Optic Neuropathy Treatment Forecast
10.2 Americas Ischemic Optic Neuropathy Treatment Forecast by Country (2026-2031)
10.2.1 United States Market Ischemic Optic Neuropathy Treatment Forecast
10.2.2 Canada Market Ischemic Optic Neuropathy Treatment Forecast
10.2.3 Mexico Market Ischemic Optic Neuropathy Treatment Forecast
10.2.4 Brazil Market Ischemic Optic Neuropathy Treatment Forecast
10.3 APAC Ischemic Optic Neuropathy Treatment Forecast by Region (2026-2031)
10.3.1 China Ischemic Optic Neuropathy Treatment Market Forecast
10.3.2 Japan Market Ischemic Optic Neuropathy Treatment Forecast
10.3.3 Korea Market Ischemic Optic Neuropathy Treatment Forecast
10.3.4 Southeast Asia Market Ischemic Optic Neuropathy Treatment Forecast
10.3.5 India Market Ischemic Optic Neuropathy Treatment Forecast
10.3.6 Australia Market Ischemic Optic Neuropathy Treatment Forecast
10.4 Europe Ischemic Optic Neuropathy Treatment Forecast by Country (2026-2031)
10.4.1 Germany Market Ischemic Optic Neuropathy Treatment Forecast
10.4.2 France Market Ischemic Optic Neuropathy Treatment Forecast
10.4.3 UK Market Ischemic Optic Neuropathy Treatment Forecast
10.4.4 Italy Market Ischemic Optic Neuropathy Treatment Forecast
10.4.5 Russia Market Ischemic Optic Neuropathy Treatment Forecast
10.5 Middle East & Africa Ischemic Optic Neuropathy Treatment Forecast by Region (2026-2031)
10.5.1 Egypt Market Ischemic Optic Neuropathy Treatment Forecast
10.5.2 South Africa Market Ischemic Optic Neuropathy Treatment Forecast
10.5.3 Israel Market Ischemic Optic Neuropathy Treatment Forecast
10.5.4 Turkey Market Ischemic Optic Neuropathy Treatment Forecast
10.6 Global Ischemic Optic Neuropathy Treatment Forecast by Type (2026-2031)
10.7 Global Ischemic Optic Neuropathy Treatment Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Ischemic Optic Neuropathy Treatment Forecast
11 Key Players Analysis
11.1 AbbVie
11.1.1 AbbVie Company Information
11.1.2 AbbVie Ischemic Optic Neuropathy Treatment Product Offered
11.1.3 AbbVie Ischemic Optic Neuropathy Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 AbbVie Main Business Overview
11.1.5 AbbVie Latest Developments
11.2 Eli Lily Company
11.2.1 Eli Lily Company Company Information
11.2.2 Eli Lily Company Ischemic Optic Neuropathy Treatment Product Offered
11.2.3 Eli Lily Company Ischemic Optic Neuropathy Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 Eli Lily Company Main Business Overview
11.2.5 Eli Lily Company Latest Developments
11.3 GlaxoSmithKline
11.3.1 GlaxoSmithKline Company Information
11.3.2 GlaxoSmithKline Ischemic Optic Neuropathy Treatment Product Offered
11.3.3 GlaxoSmithKline Ischemic Optic Neuropathy Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 GlaxoSmithKline Main Business Overview
11.3.5 GlaxoSmithKline Latest Developments
11.4 Pfizer Inc.
11.4.1 Pfizer Inc. Company Information
11.4.2 Pfizer Inc. Ischemic Optic Neuropathy Treatment Product Offered
11.4.3 Pfizer Inc. Ischemic Optic Neuropathy Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Pfizer Inc. Main Business Overview
11.4.5 Pfizer Inc. Latest Developments
11.5 Teva Pharmaceuticals
11.5.1 Teva Pharmaceuticals Company Information
11.5.2 Teva Pharmaceuticals Ischemic Optic Neuropathy Treatment Product Offered
11.5.3 Teva Pharmaceuticals Ischemic Optic Neuropathy Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Teva Pharmaceuticals Main Business Overview
11.5.5 Teva Pharmaceuticals Latest Developments
11.6 Bausch Health Companies
11.6.1 Bausch Health Companies Company Information
11.6.2 Bausch Health Companies Ischemic Optic Neuropathy Treatment Product Offered
11.6.3 Bausch Health Companies Ischemic Optic Neuropathy Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Bausch Health Companies Main Business Overview
11.6.5 Bausch Health Companies Latest Developments
11.7 F. Hoffmann-La Roche AG
11.7.1 F. Hoffmann-La Roche AG Company Information
11.7.2 F. Hoffmann-La Roche AG Ischemic Optic Neuropathy Treatment Product Offered
11.7.3 F. Hoffmann-La Roche AG Ischemic Optic Neuropathy Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 F. Hoffmann-La Roche AG Main Business Overview
11.7.5 F. Hoffmann-La Roche AG Latest Developments
11.8 Bayer AG
11.8.1 Bayer AG Company Information
11.8.2 Bayer AG Ischemic Optic Neuropathy Treatment Product Offered
11.8.3 Bayer AG Ischemic Optic Neuropathy Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Bayer AG Main Business Overview
11.8.5 Bayer AG Latest Developments
11.9 Sanofi A.S.
11.9.1 Sanofi A.S. Company Information
11.9.2 Sanofi A.S. Ischemic Optic Neuropathy Treatment Product Offered
11.9.3 Sanofi A.S. Ischemic Optic Neuropathy Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 Sanofi A.S. Main Business Overview
11.9.5 Sanofi A.S. Latest Developments
11.10 Bristol-Myers Squibb and Company
11.10.1 Bristol-Myers Squibb and Company Company Information
11.10.2 Bristol-Myers Squibb and Company Ischemic Optic Neuropathy Treatment Product Offered
11.10.3 Bristol-Myers Squibb and Company Ischemic Optic Neuropathy Treatment Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 Bristol-Myers Squibb and Company Main Business Overview
11.10.5 Bristol-Myers Squibb and Company Latest Developments
12 Research Findings and Conclusion

License Types: 

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

Source URL:/lpi/global-ischemic-optic-neuropathy-treatment-market-growth-status-and-outlook-2025-2031

Links
[1] /countries/global[2] /pharmaceutical-manufacturing[3] /healthcare[4] /pharma-healthcare